Matinas BioPharma Holdings, Inc. has granted stock options to its director, D An Evelyn, as part of its ongoing efforts to align management incentives with shareholder interests. This move is significant as it reflects the company's strategy to motivate its leadership while ensuring they remain committed to the company’s long-term success.

Background

Matinas BioPharma Holdings, Inc. operates in the pharmaceutical preparations industry, classified under SIC 2834. The company is publicly traded on the NYSE under the ticker symbol MTNB. As a smaller reporting company, Matinas is focused on developing innovative therapies aimed at improving patient outcomes.

What the Filing Says

According to the recent filing dated November 6, 2026, D An Evelyn was granted an option to purchase 5,000 shares of the company's common stock at an exercise price of $1.16. The option will vest fully upon the earlier of a year from the grant date or a change in control, contingent on Evelyn's continued service.

Impact

This stock option grant may affect the company's strategic direction by incentivizing Evelyn to enhance shareholder value. It reflects Matinas's approach to executive compensation, which could influence other firms in the pharmaceutical preparations sector as they consider similar compensation structures.

What's Next

The filing does not say what happens next.